Pluristem Therapeutics Inc. (Nasdaq:PSTI) is a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products , derived from human placenta, for the treatment of several severe ischemic and autoimmune disorders.

29 June 2009
Pluristem Therapeutics was Awarded a $1.9 Million Grant from the Office of the Chief Scientist in the Israeli Government

---

16 June 2009
Pluristem Therapeutics Receives European Regulatory Approval for Placental-Derived Stem Cell Clinical Trial
Approval Paves Way for US and European Trials That Will Enroll Patients Diagnosed with Critical Limb Ischemia Who are Facing Amputation

---

10 June 2009
Pluristem Therapeutics to Present at the Second Annual Life Science Conference of The Society of Investment Professionals in Germany

---

8 June 2009
Pluristem Therapeutics to Present at the 8th Israel Life Science Industry (ILSI) BioMed Conference

---

2 June 2009
Stanford's Professor John Cooke Joins Pluristem's Scientific Advisory Board

---

26 May 2009
Pluristem Therapeutics to Present at the International Society for Stem Cell Research (ISSCR) 7th Annual Meeting

---

12 May 2009
Pluristem Therapeutics to Present at the Center for Finance Education

---

6 May 2009
Pluristem Therapeutics Announces $1.3 Million Securities Offering with Two Institutional Investors.
Healthcare fund to subscribe to the majority of the offering

---

5 May 2009
Pluristem Therapeutics Announces Major Clinical Site in North Carolina for PLX-PAD Phase-I Trial

---

5 May 2009
Pluristem Therapeutics to Present at the 2009 BIO International Convention as Part of the Israeli Delegation

---

28 April 2009
Pluristem Therapeutics to Present Its Clinical Path at the International Society for Cellular Therapy (ISCT) 15th Annual Meeting

---

20 April 2009
Pluristem Therapeutics to Present at the Tel-Aviv Stock Exchange

---

7 April 2009
Pluristem Therapeutics to Sponsor the World Conference on Regenerative Medicine

---

31 March 2009
Pluristem Therapeutics to Present at the German Equity Forum

---

17 March 2009
Pluristem Therapeutics to Present at “The Stem Cell Network” Conference

---

09 March 2009
Pluristem Therapeutics Prepares for Placental-Derived Stem Cell Clinical Trial

---

02 March 2009
Pluristem Therapeutics Receives FDA Clearance to Begin “First-In-Human” Placenta-Derived Stem Cell Clinical Trial

---

17 Feb 2009
Pluristem Therapeutics to Present at Italian CREM Workshop Focused on Placental-Derived Cells

---

11 Feb 2009
Pluristem Therapeutics Appoints Dr. Frida Grynspan to Vice President of Research and Development

---

11 Feb 2009
Pluristem Receives Deficiency and Compliance Notice from Nasdaq.
Company is Now in Compliance

---

02 Feb 2009
Pluristem Therapeutics’ cGMP Facilities Approved for Clinical Manufacturing in Europe

---

30 Jan 2009
Pluristem Therapeutics Announces US $1,200,000 Restricted Share Purchase

---

27 Jan 2009
Pluristem Therapeutics Collaborates with the Charité - Universitätsmedizin Berlin and Franziskus-Krankenhaus Hospital for its Clinical Trials in Germany

---

20 Jan 2009
Pluristem Therapeutics to Present at the 19th Israeli Medical Association World Fellowship International Conference

---

13 Jan 2009
Pluristem Therapeutics Files an IND Application with the FDA to Initiate a Phase I Clinical Trial Utilizing PLX-PAD for Critical Limb Ischemia

---

For more News